OncoMatch/Clinical Trials/NCT06653517
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Is NCT06653517 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Dabrafenib and Trametinib for ameloblastoma.
Treatment: Dabrafenib · Trametinib — This study aims to evaluate the tumor shrinkage effect of preoperative targeted induction therapy with dabrafenib and trametinib in patients with conventional ameloblastoma harboring the BRAF V600E mutation. The study will assess the proportion of cases where mandibular continuity cannot be preserved that can be converted to cases where mandibular continuity is preserved, as well as the proportion of cases where complete resection is initially not feasible that become resectable.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Biomarker criteria
Required: BRAF v600e
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: BRAF inhibitor (dabrafenib)
Previous use of dabrafenib
Cannot have received: MEK inhibitor (trametinib)
Previous use of trametinib
Cannot have received: BRAF inhibitor
Previous use of other BRAF inhibitors
Cannot have received: MEK inhibitor
Previous use of other MEK inhibitors
Lab requirements
Blood counts
wbc ≥ 4.0×10^9/l, anc ≥ 1.5×10^9/l, plt ≥ 100×10^9/l, hb ≥ 90g/l (no transfusion or blood products, no use of g-csf or other hematopoietic stimulants within 14 days)
Kidney function
bun/cre ≤ 1.5×uln or creatinine clearance rate ≥ 60 ml/min
Liver function
tbil ≤ 1.5×uln, alt/ast ≤ 2.5×uln
Cardiac function
no myocardial infarction, severe/unstable angina, nyha class ii or higher heart failure, significant arrhythmias, or symptomatic congestive heart failure within 6 months before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06653517 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BRAF inhibitor, MEK inhibitor, BRAF inhibitor disqualifies patients from enrollment.
Does this trial require BRAF?
Yes, BRAF v600e is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify